Abstract
IntroductionThe role of HOXB13 in bladder and renal tumorigenesis is unclear. Our goal was to determine the prevalence of HOXB13 p.G84E mutation in bladder and kidney cancer patients from Poland.Materials and methods1418 patients with bladder cancer and 813 cases with kidney cancer and 4497 controls were genotyped for HOXB13 p.G84E.Resultsp.G84E mutation of HOXB13 gene was detected in three of 1418 (0.2%) bladder cancer cases and in six of 4497 controls (odds ratio [OR], 1.6; 95% CI 0.39–6.36; p = 0.8). Among 813 kidney cancer cases HOXB13 mutations was reported in three patients (0,4%) (odds ratio [OR], (OR = 2,8; 95% CI 0.69–11.11; p = 0.3). In cases with mutations in the HOXB13 gene, the family history of cancer was negative.ConclusionHOXB13 mutation was not associated with bladder or kidney cancer. Mutation p.G84E in HOXB13 seem not to play a role in bladder and kidney cancer development in Polish patients.
Highlights
The role of HOXB13 in bladder and renal tumorigenesis is unclear
Bladder cancer Of the 1418 bladder cancer patients enrolled in the study, three (0.2%) carried a HOXB13 mutation p.G84E (OR = 1.6; 95% CI 0.39–6.35; p = 0.8) (Table 1)
In this study, we found no impact of the p.G84E mutation in the HOXB13 gene on bladder or kidney cancer
Summary
Our goal was to determine the prevalence of HOXB13 p.G84E mutation in bladder and kidney cancer patients from Poland. In men one of the most common cancers of the urinary tract is bladder cancer 7% and kidney cancer - 4%. Bladder cancer accounts for less than 1% and kidney cancer for 2.5% of all cancer cases [1]. The exact molecular mechanisms underlying the initiation and progression of bladder or kidney cancer remain largely unknown. High hereditary predisposition for bladder cancer is presents in 4% and for kidney cancer 5% [2, 3]. A number of mechanisms play a large role in the initiation of neoplastic transformation of bladder or kidney cancer, including: mutation of suppressor genes, activation of proto-oncogenes, abnormal and Złowocka-Perłowska et al Hereditary Cancer in Clinical Practice
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
